Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The new coronavirus known as SARS-Cov-2 (severe acute respiratory syndrome -coronavirus 2) was first reported in December 2019 and rapidly became a public health emergency. The COVID-19 pandemic is now affecting sensitive regions with fragile health care systems, such as South America and Africa. Caregivers, in the front line of Covid19 patient management, may accidentally become infected and a source of infection during the incubation phase or in case of asymptomatic infection.
The objectives of this project are thus i) to assess SARS-Cov-2 spread over the hospital departments of Bamako by carrying out a systematic molecular screening of patients and caregivers, ii) to evaluate the feasibility of Point-Of-Care molecular assays in Mali and iii) to estimate the immunity acquired from SARS-Cov-2 among health workers through serological testing, allowing also the assessment of asymptomatic caregiver rate and absence of re-infection among the immunized caregivers. Finally, iv) variability of the virus over time and spread of different variants around the world will be studied by sequencing the viral genome.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients | Experimental | - Hospitalized patients in one of the four centers in Bamako, with clinical signs of infection of the upper or lower respiratory tracts with fever or feeling of fever or any other signs of SARS-Cov-2 infection or who have been in close contact with a SARS-CoV-2 infected person without effective protective measures |
|
| Caregivers | Experimental | Caregivers of one of the four centers in Bamako.
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SARS-CoV-2 screening by molecular biology | Diagnostic Test | SARS-CoV-2 RT-PCR in nasopharyngeal swab targeting 2 regions of the viral genome |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence rate of positive SARS-Cov-2 RT-PCR in Bamako hospital departments during the study | Positive SARS-Cov-2 RT-PCRs are defined by the detection of SARS-Cov-2 genome after amplification using a test targeting 2 regions of the genome. | Through the completion of subject participation (up to 15 months after study start date). |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Cepheid Xpert® Xpress SARS-Cov-2 cartridges available for 19.8 USD/number required for the project | Through the completion of subject participation (up to 15 months after study start date). | |
| Percentage of positive serological tests among the caregivers of the hospital departments of Bamako. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Almoustapha Issiaka MAIGA | SEREFO/UCRC, FMOS - University Hospital Gabriel Toure, Bamako, Mali | Principal Investigator |
| Eve Todesco | APHP - Sorbonne university | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hopital du Point-G | Bamako | Mali | ||||
| Hopital Gabriel Toure |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35182761 | Result | Maiga AI, Saliou M, Kodio A, Traore AM, Dabo G, Flandre P, Fofana DB, Ammour K, Tra NOME, Dolo O, Marcelin AG, Todesco E. High SARS-CoV-2 seroprevalence among health care workers in Bamako referral hospitals: a prospective multisite cross-sectional study (ANRS COV11). Clin Microbiol Infect. 2022 Jun;28(6):900-902. doi: 10.1016/j.cmi.2022.02.019. Epub 2022 Feb 16. No abstract available. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Interventions
Not provided
Not provided
Not provided
Not provided
| Serological screening | Diagnostic Test | Serological screening of caregivers at D0, M1, M2, M3 (anti-nucleocapsid antibodies). |
|
| Assessed on the fourth serological assay performed (at Month 3). |
| Percentage of caregivers asymptomatic but immunized to SARS-CoV-2 | Assessed on the fourth serological assay performed (at Month 3). |
| Percentage of caregivers immunized and re-infected with SARS-CoV-2 | Through the completion of caregiver participation (up to 15 months after study start date). |
| Number of SARS-CoV-2 mutations/variants detected during the study | Through the completion of subject participation (up to 15 months after study start date). |
| Percentage of SARS-CoV-2 mutations/variants detected during the study | Through the completion of subject participation (up to 15 months after study start date). |
| Bamako |
| Mali |
| Hôpital dermatologique de Bamako | Bamako | Mali |
| Hôpital du Mali | Bamako | Mali |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |